Prestige Consumer Healthcare Reaffirms 2024 Sales Guidance Of $1.135B-$1.14B Versus Consensus Of $1.14B, With Free Cash Flow Of Over $240M
Portfolio Pulse from Benzinga Newsdesk
Prestige Consumer Healthcare has reaffirmed its sales guidance for 2024, projecting sales between $1.135 billion and $1.14 billion, aligning closely with the consensus estimate of $1.14 billion. Additionally, the company expects to generate over $240 million in free cash flow.
February 08, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prestige Consumer Healthcare reaffirms its 2024 sales guidance, expecting sales between $1.135B and $1.14B, with free cash flow over $240M.
Reaffirming sales guidance, especially when it aligns with consensus estimates, typically instills confidence in investors about the company's financial health and future performance. The announcement of expected strong free cash flow further supports a positive outlook, likely leading to a positive short-term impact on PBH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90